Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 2008

View Archived Issues

Daiichi Sankyo updates recent activity

AVI initiates next-generation drug eluting stent trial with Global Therapeutics

Novexel commences phase II for NXL-104/ceftazidime combination in UTIs

Quigley completes phase IIb study of QR-333 in diabetic peripheral neuropathy

Vical completes enrollment in phase II CMV vaccine trial

Phase IIa results with INCB-018424 in rheumatoid arthritis lead to phase IIb trials

Phase I data reported for autoimmune disorders candidate LX-2931

RAPID data show radiographic activity in nonresponders, sustained benefits in extension study

HIV protease inhibitor saquinavir kills ovarian cancer cells

ACH-702: new data on preclinical antibacterial activity, pharmacokinetics

Pfizer reports on sulopenem prodrug antibiotics

Seroquel approved in Europe for new indications in bipolar disorder

Sevikar approved in Germany for hypertension

Sanofi-aventis reports new post hoc results from ATHENA trial of Multaq in AF/AFL

Boehringer announces results from the PETRO-Ex study of Pradaxa for stroke in AF

Yissum and BioLineRx enter license agreement for antihormone BL-5040 in IBD

Swissmedic approves ceftobiprole for complicated skin and soft tissue infections

Nymox reports positive results in 59-week study of NX-1207 for BPS

Novel antiobesity agents disclosed in recent patents

Recent Novartis patent discloses novel antiinflammatory agents

New diagnostic agents imparted by Merck Eprova

Antyra and Novo Nordisk sign licensing agreement for IGF antagonists

Ensemble and Roche extend collaboration for diagnostic technology in cancer therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
EASL spotlight: TUNE-401 advances epigenetic silencing in HBV
BioWorld
Several presentations at EASL highlight a new generation of therapies coming into view, with the work from Tune Therapeutics Inc. standing out as one of the most...